Conference Coverage (Retrovirus)

p24 Emerges As Target HIV Vaccine Antigen

Published in Vaccine Weekly, March 10th, 1997

Cellular immune responses directed against the HIV p24 capsid protein may protect against HIV disease.

Researchers attempting to create an HIV vaccine have long been shooting in the dark, not knowing what immunity to HIV looks like. Definitive correlates of immunity to the virus have never been identified.

Now a beam of light has lit the target. It emanates from a single individual who has battled the virus to a standstill. After 16 years of HIV infection, this person has remained immunologically and clinically healthy with a very low viral load (<400 HIV RNA copies/mL plasma) and a normal CD4 count (1440 cells/(mu)L).

Eric...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1997-03-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry